Search results
Results From The WOW.Com Content Network
New research suggests that slowly tapering off GLP-1 drugs like Ozempic and Wegovy may help prevent rebound weight gain. Yoshiyoshi Hirokawa/Getty Images This article originally appeared on Healthline
Weight gain. Some side effects, such as weight gain, occur more frequently with certain types of antidepressant medication. ... cross-tapering or tapering down your dosage before you start using ...
Common side effects may include cataracts, bone loss, easy bruising, muscle weakness, and thrush. [3] Other side effects include weight gain, swelling, high blood sugar, increased risk of infection, and psychosis. [4] [3] It is generally considered safe in pregnancy and low doses appear to be safe while the user is breastfeeding. [5]
GLP-1 drugs used for weight loss involve all kinds of side effects—good and not-so-good—that may or may not strike the average user. (Reminder that there are many of these meds now. GLP-1s ...
[7] [8] [6] It differs from the similarly named prednisone in having a hydroxyl at the 11th carbon instead of a ketone. Common side effects with short-term use include nausea, difficulty concentrating, insomnia, increased appetite, and fatigue. [5] More severe side effects include psychiatric problems, which may occur in about 5% of people. [9]
The most common side effects of these drugs that led to withdrawals were mental disturbances, cardiac side effects, and drug abuse or drug dependence. Deaths were associated with seven products. [84] Ephedra was removed from the US market in 2004 over concerns that it raises blood pressure and could lead to strokes and death. [85]
Cushing's syndrome is a collection of signs and symptoms due to prolonged exposure to glucocorticoids such as cortisol. [4] [9] [10] Signs and symptoms may include high blood pressure, abdominal obesity but with thin arms and legs, reddish stretch marks, a round red face due to facial plethora, [11] a fat lump between the shoulders, weak muscles, weak bones, acne, and fragile skin that heals ...
Pfizer announced on Dec. 1 that it was discontinuing phase 3 clinical trials of the twice-daily version due to high rates of adverse side effects. While these were mostly mild, a large percentage ...